Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement-Reference-Cited by-同舟云学术

Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Published:2024-05-08 Issue: Volume: Page:
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Manzo Ciro¹^ORCID,Natale Maria¹,Isetta Marco²,Castagna Alberto³

Affiliation:

1. Internal and Geriatric Medicine Department, Rheumatology Outpatient Clinic, Health District No. 59 , Naples, Italy

2. Library and Knowledge Services, Central and North West London NHS Foundation Trust , London, UK

3. Primary Care Department, Azienda Sanitaria Provinciale Catanzaro , Catanzaro, Italy

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keae259/58101201/keae259.pdf

Reference11 articles.

1. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement;Vermeulen;Rheumatology (Oxford),2024

2. 2012 provisional classification criteria for polymyalgia rheumatica: a European Leaugue Against Rheumatism/American College of Rheumatology collaborative initiativa;Dasgupta;Ann Rheum Dis,2012

3. Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica;Muratore;Reumatismo,2018

4. Polymyalgia rheumatica: diagnostic and therapeutic issues of an apparently straightforward disease;Manzo;Recenti Prog Med,2017

5. Pathogenesis of polymyalgia rheumatica;Guggino;Reumatismo,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply;Rheumatology;2024-05-13